Skip to main content
A. Fabarius on Muck Rack

A. Fabarius

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with A.

Contact A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

|
By P. Panayiotidis, J. H. Richter, D. Nowak, P. Ljungman, T. H. Brümmendorf, W. Majeed, S. Rinaldetti, M. Chepeleva, A. Hedblom, C. Sticht, M. Muciek, U. Olsson-Strömberg, V. Nowak, N. von Bubnoff, K. Lotfi, L. Stenke, H. Hjorth-Hansen, T. Gedde-Dahl, A. Burchert, P. V. Nazarov, E. Felde, I. Tarnopolscaia, C. Hoelting, A. Fabarius, W.-K. Hofmann, F.-X. Mahon, S. Saussele, M. Pfirrmann
| Nature Verified
Abstract The European Stop Kinase Inhibitors (EURO-SKI) trial was launched to investigate the discontinuation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). The molecular mechanisms underlying sustained treatment-free remission (TFR) and loss of TFR, are still poorly understood. To address this, we performed whole transcriptome gene expression analyses coupled with NanoString nCounter-based absolute gene quantification.
Open in Who Shared Issue with article?
See all 1 articles